论文部分内容阅读
目的 :探讨再生障碍性贫血 (再障 )患者HLAⅡ类单体型DRB 115 0 1阳性率及临床意义。方法 :随机检测再障患者HLAⅡ单体型DRB 115 0 1、分析其阳性率与临床类型、发病机理分组 ,环孢霉素A(CSA)体外干预试验结果等关系。结果 :2 3例再障 10例阳性 ,阳性率 43 .5 %。结论 :再障HLAⅡ类单体DRB 115 0 1阳性与CSA体外干预试验结果类似 ,且绝大多数患者呈一致性改变 ,为再障CSA的个体化治疗方案的制定提供了实验依据。
Objective: To investigate the positive rate of HLA class II haplotype DRB 115 0 in patients with aplastic anemia (aplastic anemia) and its clinical significance. Methods: The HLA Ⅱ haplotype DRB 115 0 was randomly detected in patients with aplastic anemia. The relationship between the positive rate and the clinical type, pathogenesis group and the in vitro intervention test of cyclosporin A (CSA) were analyzed. Results: Twenty cases of aplastic anemia were positive in 10 cases and the positive rate was 43.5%. CONCLUSION: The positive results of DRB 115 0 in patients with aplastic anemia HLA class II are similar to those of CSA in vitro. The majority of patients are consistent with the changes, providing an experimental basis for the development of individualized treatment regimens of CSA.